Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
This is not a financial advice!
Upcoming catalyst 04/09/2024
Shs Float 11.97M
Rel. Vol. on 03/15/2024 at 7.25
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 7.5 / 8.0 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 5.5
TP approx. 10
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalyst 04/09/2024
Shs Float 11.97M
Rel. Vol. on 03/15/2024 at 7.25
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 7.5 / 8.0 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 5.5
TP approx. 10
Most info on the chart.
Trade carefully!
Trade closed: stop reached
Comment:
SL was too close
Comment:
Acrivon Therapeutics stock surges on $130M private placement financing
DAMN
DAMN